A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Parkinson's DiseaseTo establish the efficacy of 40 mg/day doses of istradefylline for the change in Unified Parkinson's Disease Rating Scale (UPDRS) part-III (Motor examination) score in patients with Parkinson's disease (PD).
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy...
Parkinson's DiseaseThe purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off....
Parkinson's DiseaseThe purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiting patients in the United States.
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's...
Idiopathic Parkinson's DiseaseThe objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic Parkinson's disease.
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa...
Parkinson's DiseaseStudy to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
Parkinson DiseaseThe objective of this study was to measure the continued efficacy of apomorphine after previous exposure of at least three months duration.
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Parkinson DiseaseStudy to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007,...
Parkinson's DiseaseThis is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Parkinson's DiseaseMovement Disorder SyndromeThe primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
Parkinson DiseaseDyskinesiasThe purpose of this study is to study different kinds of dyskinesias in advanced Parkinson's disease appearing at different levels of levodopa infusion dose. The hypothesis is that different dyskinesias (dystonia, chorea) correlate to different levels of levodopa concentrations, as detected in plasma.